Navigation Links
Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Date:3/6/2013

CARLSBAD, Calif., March 6, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 2:00 p.m. ET in Miami, FL.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets, including Europe.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
2. Tarix Pharmaceuticals Peptide Technology Stimulates Revascularization Following Ischemia
3. Aquavit Pharmaceuticals Inc. Appoints David Shafer, MD., FACS., New Chief Medical Technology Officer
4. TauRx Pharmaceuticals Receives $10.5m Follow-On Investment from Dundee Corporation
5. Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
6. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
7. Auxilium Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Healthcare Conference
8. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
9. AVANIR Pharmaceuticals To paticipate in two conferences in March
10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
11. Adamis Pharmaceuticals Prevails in License Dispute Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... BROOMALL, Pa. , May 3, 2016 ... Attorney Jack Whelan and Delaware County ... NARCAN® (naloxone HCI) Nasal Spray in all ACME ... the U.S. Centers for Disease Control and Prevention (CDC), naloxone has ... 2014, when police officers in Delaware County ...
(Date:5/3/2016)... (NYSE: DPLO) announced today that it is celebrating Hepatitis Awareness Month with a campaign to ... personal story and encourage those at risk to get tested and begin the road to ... ... ... (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... , May 3, 2016 Intec ... a clinical-stage biopharmaceutical company, today announced the appointment of ... Regulatory Affairs. "Ms. Strauss-Levy has 15 years ... has established an outstanding track record, having supported the ... regulatory approval processes in the United States ...
Breaking Medicine Technology:
(Date:5/4/2016)... , ... May 04, 2016 , ... ... Dr. Todd Rider's research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have ... campaign that starts on May 3, 2016 at http://igg.me/at/EndTheVirus and runs ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... and Continence Nurses (WOCN) Society™ and Canadian Association for Enterostomal Therapy (CAET) ... promotion, time saving and planning tools to attendees and exhibitors for the 2016 ...
(Date:5/4/2016)... ... May 04, 2016 , ... May kicked off with ... across the United States. Dermatologist Dr. Ellen Turner is encouraging her patients, as well ... and focus on skin safety and health now and in the future. , The ...
(Date:5/4/2016)... ... May 04, 2016 , ... Recognizing that lifestyle medicine is essential ... Verywell, have tapped David Katz, MD, MPH, president of the American College of ... to lifestyle medicine is especially gratifying,” said Katz. “There is so much opportunity to ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and NSR-9844XL ... (average retail starting at $59.95) uses 2 included CR-123 batteries to produce up ...
Breaking Medicine News(10 mins):